Glaxo's Imitrex injectable sumatriptan
Executive Summary
Will be reviewed for use in the treatment of migraine by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Oct. 25. Glaxo filed the NDA (#20-080) for injectable sumatriptan on June 29, 1990 and filed for approval of a slower-acting oral form on Dec. 14, 1990. On Oct. 24, the advisory committee meeting will be closed to discuss trade secret and/or confidential information on pending INDs. Glaxo's drug will be reviewed in an open meeting scheduled for 8 a.m.-5 p.m. The committee will meet at FDA's Parklawn Bldg., Conference Rooms D&E. . . .